PROVENTAI N T E R N A T I O N A L

1

TRACK 2 - MEDCHEM DESIGN & CUSTOM SYNTHESIS

TRACK 1 - MEDCHEMARTIFICIAL INTELLIGENCE / MACHINE LEARNING

TRACK 4 - MEDCHEM HIT TO LEAD IDENTIFICATION

TRACK 3 - MEDCHEM INTEGRATED DRUG DISCOVERY

TRACK 6 - MEDCHEMDISRUPTIVE TECHNOLOGIES

TRACK 5 - MEDCHEM CHEMICAL BIOLOGY & CHEMINFORMATICS

TRACK 8 - BIOLOGY DMPK & ADME

TRACK 7 - BIOLOGY OUTSOURCING FOR EMERGING BIOPHARMA

TRACK 10 - BIOLOGY IND- PROOF OF CONCEPT

TRACK 9 - BIOLOGY IN VIVO & IN VITRO PHARMACOLOGY

TRACK 12 - BIOLOGYTARGET VALIDATION

TRACK 11 - BIOLOGY STRATEGIC PARTNERSHIP & OUTSOURCING

2019 ATTENDEES

AGENDA BIOLOGY

AGENDA MED-CHEM

SPONSORS

Click here to find out what our clients think about our Strategy Meetings

Laurent AudolyCEO & FounderParthenon Therapeutics

Paul Peter Tak MD PhD President & CEO Kintai Therapeutics

Rob HowesDirector Discovery Biology AstraZeneca

Jascha BlobelCEO Molomics

Tim Sparey CEO Novintum Bioscience

PJ Moloney CEO P4ML

Asif Ahmed Founder MirZyme Therapeutics

Tobias GabrielHead, External Science & Drug DiscoveryNovartis

Garry Pairaudeau Head of Hit Discovery AstraZeneca

Lassina BadoloDirector Discovery DMPK Merck

OUR UNIQUE ONLINE MEETING FORMAT CONTRIBUTORS TO THE AGENDA

Roundtable DiscussionsThese interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

Personalised AgendaEach delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent on the online platform is focused and well-utilised.

One-to-one MeetingsThe most effective and time efficient way to assess potential partners at a strategic level. Gain access to our exclusive networking app to identify the people that you need to meet. The app will allow for instant anddirect messaging to organise online meetings during the dedicated time to most benefit you.

Strategic NetworkingStrategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.

2020JUNESTRATEGY 29thONLINE MEETING

http://

PROVENTAI N T E R N A T I O N A L

1 GO TO MENU NEXT PAGEPREVIOUS PAGE

PRO-PARTNERS

VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE

CO-HOST

VISIT WEBSITE

VISIT WEBSITE

Dotmatics delivers a ready-to-use platform to capture, register, share, collaborate, query, visualise and analyse all the information and knowledge generated in the modern, highly collaborative scientific industries. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. The enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing.

VISIT WEBSITE

LAXAI is a fully integrated contract research and development organization that delivers solutions in drug discovery, chemical process R&D, and GMP manufacturing for innovator pharmaceutical, Biotech, and animal health companies globally. Over the years, our focus has been on providing highly efficient scientific solutions, which has enabled us to partner on more than 20 integrated drug discovery programs and multiple medicinal chemistry focused FTE collaborations. As a result, we have delivered clinical candidates and technology platforms across diverse therapeutic areas. Further, owing to our strength in chemistry and our experience in solving complex problems, we have been engaged on a number of chemical process R&D and GMP manufacturing projects by innovator pharmaceutical companies. This experience, spanning more than a decade, has enabled us to develop deep expertise in custom NCEs, and custom manufactured advanced intermediates and fine chemicals.

VISIT WEBSITE

Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines with our partners by 2025. Sai Life Sciences provides services to our pharma innovator partners, which accelerate the discovery, development and manufacture of complex small molecule therapeutic agents. Our clients gain clear competitive advantages through shorter time to market and risk minimization using our integrated and high-quality scientific services. Established in 1999, Sai has over 2,000 employees located at six R&D and manufacturing sites in India, the UK and USA. As one of India’s fastest growing CDMOs, the company is investing over US $ 150 M in augmenting its R&D and manufacturing capabilities, including setting up a Biology Lab in Cambridge, Mass. (USA) and a Process R&D Lab in Manchester, UK. Sai provides high value integrated services in all areas of chemistry from hit discovery to GMP manufacturing, pharmacology, DMPK, toxicology and formulation development to better support the increasing needs of our customers. Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.

VISIT WEBSITE

At Proventa Talent, we always look ahead to ensure that the service we deliver to you is second to none, both now and in the future. Proventa Talent based around our three key principles of commitment, intelligence and partnership ensures an unparalleled recruitment solution in the industry. We work with the leading talent in the field to offer a service of high quality, efficiency and transparency. In addition to this, our relationship with many organisations across the Life Sciences sector means that we are constantly developing our recruitment services to offer market-leading solutions including Contingency, Executive Search, Contract and fully integrated Recruitment Process Outsourcing to suit your short, medium and long term needs. VISIT WEBSITE

Sygnature Discovery is a leading integrated drug discovery and pre-clinical services company. We operate fully equipped modern research facilities in Nottingham and Alderley Park, UK, housing over 300 research scientists (>80% with PhDs). Our experienced drug hunters possess all the professional skills and know-how to enable success in the most demanding of research programmes and drive them from target validation through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate. Since 2011, we have delivered 31 drug candidates to our clients, 15 of which have subsequently entered the clinic (Phases I, II and III). To find out more about us, visit our website: www.sygnaturediscovery.com

VISIT WEBSITE

Nanome, the first virtual reality (VR) software company to launch an immersive real-time collaboration platform for scientific discovery, is changing the way we understand and interact with science at the molecular level. The software environment allows users to visualize, modify, and simulate proteins, chemical compounds, and nucleic acids to accelerate scientific decision making. The platform facilitates effective communication of data and integrates with existing computational chemistry workflows—features that have led to the adoption of the San Diego–based company’s enterprise solution by several pharmaceutical and biotech companies worldwide. For more information, visit nanome.ai

SPONSORS

2 PROVENTAI N T E R N A T I O N A L

GO TO MENU

NETWORKING BREAK1 - 1 MEETING *13:30-13:50 B.S.T. NETWORKING BREAK

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUND TABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

12:00 - 12:30

19:20 - 20:20

14:30 - 15:30

18:00 - 19:00

13:30 - 14:30

19:00 - 19:20

12:30 - 13:30

15:30 - 17:30

17:30 - 18:00

1 - 1 MEETING *19:00-19:20 B.S.T.

KEYNOTE PRESENTATION KEYNOTE PRESENTATIONKEYNOTE PRESENTATION

Tobias Gabriel - HeadNovartis

Jascha Blobel - CEO Molomics

Mauro Marigo - Head Medicinal Chem.Endogena

Garry Pairaudeau - Head of Hit DiscoveryAstraZeneca

PJ Moloney - CEOP4ML

Tim Sparey - CEO Novintum Bioscience

Martin Swarbrick - Associate Director Cancer Research UK Therapeutic

Andy Merritt - Head of ChemistryLifeArc Centre

Raghava Reddy Kethiri, PhD - CSO Michael Bishop - Drug Disc. SpecialistDr Allan Jordan - Director of Oncology

Guy Lewy - CSO Sublime Therapeutics

NEXT PAGEPREVIOUS PAGE

Jonathan Hay - PartnerDelin Ventures

TIME ( *B.S.T. )AI & MACHINE LEARNING DESIGN & CUSTOM SYNTHESIS INTEGRATED DRUG DISCOVERY HIT TO LEAD IDENTIFICATION CHEMICAL BIOLOGY &

CHEMINFORMATICS DISRUPTIVE TECHNOLOGIES

Advances in drug discovery using AI

Can using AI reduce attrition rates in drug discovery?

Practical Advice on the Implementation of AI/ML in

Drug Discovery

01 02 03 0504 06

Making the molecule design cycle a success

Generative algorithms and activelearning approaches: enabling a more

automated data-driven approachto the design cycle

Optimizing Chemical Reactions with Deep Reinforcement Learning

Activation of endogenous progenitor cells by small molecules, leading to

controlled tissue repair and regeneration

Accelerating translation through strategic alliances

Speeding the drug discovery process: collaborations, partnerships and Open

Access

How will AI enhance Drug Design: Challenges and opportunities

Hit and Lead Generation: Selection of screening sets and strategies to

maximise success rates

Providing unique chemical tools to probe kinetoplastid biology and as hit-to-lead candidates for drug

discovery

Cheminformatics Tools for Analysing & Designing Optimized Small-

Molecule Collections and Libraries

Molecular adventures in 3D and 4D: What new ground is being opened up

by cloud computing?

Connecting environmental exposure and neurodegeneration using

cheminformatics : potential and challenges

High-Throughput Screening Vs MultiOMICS

How an integrated technology suite of solutions can improve compound

library acquisition and design

Targeting senescence cells

Laurent Audoly - CEO, FounderParthenon Therapeutics

TRACK & ROOM

7:00 - 7:30

14:20 - 15:20

9:30 - 10:30

13:00 - 14:00

8:30 - 9:30

14:00 - 14:20

7:30 - 8:30

10:30 - 12:30

12:30 - 13:00

TIME ( *E.T. )TRACK & ROOM

1 - 1 MEETING *13:50-14:10 B.S.T. 1 - 1 MEETING *14:10-14:30 B.S.T.

1 - 1 MEETING *15:30-15:50 B.S.T. 1 - 1 MEETING *16:10-16:30 B.S.T. 1 - 1 MEETING *16:50-17:10 B.S.T.1 - 1 MEETING *16:30-16:50 B.S.T.1 - 1 MEETING *15:50-16:10 B.S.T. 1 - 1 MEETING *17:10-17:30 B.S.T.

KEYNOTE PRESENTATION Real-world implementation of AI

Dan Ormsby - Senior Consultant - Dotmatics

KEYNOTE PRESENTATION Real-world implementation of AI

Dan Ormsby - Senior Consultant - Dotmatics

AGENDA

3 PROVENTAI N T E R N A T I O N A L

GO TO MENU

Paul Peter Tak, MD PhD - Pres. & CEOKintai Therapeutics

David Cipolla, VP of Research Insmed Inc

Marcie Glicksman, Head of Biology EnClear Therapies

Alun McCarthy - Vice PresidentC4X Discovery Ltd.

Joseph Mancini - Head of Bio., Sr Dir.adMare Bioinnovations

Isabel Najera, CSO Virion Therapeutics

Ignacio Quiles - Vice PresidentGSK

NEXT PAGEPREVIOUS PAGE

How a shared-risked partnership model can

improve the success rates of getting to IND?

The Effect of Brexit on the Emerging Biopharm sector in

the UK.

How much influence do Investors play in making a decision on where to

Outsource? Cost vs Speed vs Quality?

The use of AI for decision making in drug discovery: How can applying AI in DMPK could impact in drug

discovery?

MetID and metabolite profiling

The right technology at the right time to conduct ADME/Tox screening of a drug candidate saving time & money in the process of obtaining regulatory

approval

Live Cell in Vitro and in Vivo Imaging Applications: Accelerating

Drug Discovery

What can we still learn from cell and animal models?

Optimizing Chemical Reactions with Deep Reinforcement Learning

Bridging the gap between empirical drug discovery and rational drug development

How to get access to the secure enterprise ecosystem in order to

launch your PoC.

How to Complete a PoC without Depleting all Resources

Enabling business goals via collaborative or commercial

alliances, both moderates risk and garners reward

Implementing open innovation in the industry: Joining

pharmaceuticals, biotechs and academica together to accelerate

R&D processes.

What is a validated target? Discussion on generating new

targets for drug discovery

Using Human Genetics to Identify Drug Targets

Validated Targets through Human Biology

OUTSOURCING FOR EMERGING BIOPHARMA DMPK & ADME

IN VIVO & IN VITRO PHARMACOLOGY

IND- PROOF OF CONCEPT STRATEGIC PARTNERSHIP & OUTSOURCING TARGET VALIDATION

07 08 09 10 11 12

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUND TABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR

KEYNOTE PRESENTATION KEYNOTE PRESENTATIONKEYNOTE PRESENTATION

How to improve current alliances and gain more effective

collaborations

Asif Ahmed - FounderMirZyme Therapeutics

Lassina Badolo - Director Discovery Merck

Marc Ramis - CEOSenolytic Therapeutics

Rob Howes - Director Discovery Biology AstraZeneca

Matthew Fyfe - Head of ChemistryVirion Therapeutics

12:00 - 12:30

19:20 - 20:20

14:30 - 15:30

18:00 - 19:00

13:30 - 14:30

19:00 - 19:20

12:30 - 13:30

15:30 - 17:30

17:30 - 18:00

TIME ( *B.S.T. )TRACK & ROOM

7:00 - 7:30

14:20 - 15:20

9:30 - 10:30

13:00 - 14:00

8:30 - 9:30

14:00 - 14:20

7:30 - 8:30

10:30 - 12:30

12:30 - 13:00

TIME ( *E.T. )TRACK & ROOM

NETWORKING BREAK1 - 1 MEETING *13:30-13:50 B.S.T. NETWORKING BREAK

1 - 1 MEETING *19:00-19:20 B.S.T.

1 - 1 MEETING *13:50-14:10 B.S.T. 1 - 1 MEETING *14:10-14:30 B.S.T.

1 - 1 MEETING *15:30-15:50 B.S.T. 1 - 1 MEETING *16:10-16:30 B.S.T. 1 - 1 MEETING *16:50-17:10 B.S.T.1 - 1 MEETING *15:50-16:10 B.S.T. 1 - 1 MEETING *16:30-16:50 B.S.T. 1 - 1 MEETING *17:10-17:30 B.S.T.

Mark Bittinger, VP & Global Head of Bio.

KEYNOTE PRESENTATION Real-world implementation of AI

Dan Ormsby - Senior Consultant - Dotmatics

KEYNOTE PRESENTATION Real-world implementation of AI

Dan Ormsby - Senior Consultant - Dotmatics

AGENDA

PROVENTAI N T E R N A T I O N A L

4

LEARN MORE ABOUT OUR SPEAKERS

Dan Ormsby Senior Consultant

Dotmatics

GO TO MENU NEXT PAGEPREVIOUS PAGE

AFTERNOON KEYNOTE

TIME SLOT (*B.S.T.)

Real-world implementation of AI

Hear first hand from Dr Dan Ormsby and his ambitions to add a real-world implementation

of AI providing routine machine learning into the Dotmatics platform

17:30 - 18:00

KEYNOTEPRESENTATION

PROVENTAI N T E R N A T I O N A L

5

Tobias GabrielHead, External Science &

Drug Discovery Novartis

Tim SpareyCEO

Novintum Bioscience

SPEAKER TBC TBC TBC

Laurent AudolyCEO & Founder

Parthenon Therapeutics

Practical Advice on the Implementation of AI/ML in Drug Discovery

Title TBCAdvances in drug discovery using AI

Can using AI reduce attrition rates in drug discovery?

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

GO TO MENU NEXT PAGEPREVIOUS PAGE

TRACK 1 ARTIFICIAL INTELLIGENCE / MACHINE LEARNING

PROVENTAI N T E R N A T I O N A L

6 GO TO MENU NEXT PAGEPREVIOUS PAGE

Jascha BlobelCEO

Molomics

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC

Optimizing Chemical Reactions with Deep Reinforcement Learning

TOPIC TBC

Making the molecule design cycle a success

Generative algorithms and activelearning approaches: enabling a more

automated data-driven approachto the design cycle

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

TRACK 2 DESIGN & CUSTOM SYNTHESIS

PROVENTAI N T E R N A T I O N A L

7 GO TO MENU NEXT PAGEPREVIOUS PAGE

Mauro MarigoHead of Medicinal Chemistry

Endogena

Martin SwarbrickAssociate Director Cancer Research UK Therapeutic

Dr Allan Jordan Director of Oncology

Drug Discovery Sygnature Discovery

SPEAKER TBC TBC TBC

Speeding the drug discovery process: collaborations, partnerships and Open

Access

Internal vs. external drug discovery resources – what’s the most effective way to advance a project?

Activation of endogenous progenitor cells by small molecules, leading to controlled

tissue repair and regeneration

Accelerating translation through strategic alliances

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

• What are the pros and cons of internal vs. external drug discovery programmes?• In what way can external resources augment internal capacity and capabilities?• What are the key drivers for placing resources externally?• What are the key success factors for external collaboration?• Learning from experience – what would we do differently next time?

TRACK 3 INTEGRATED DRUG DISCOVERY

PROVENTAI N T E R N A T I O N A L

8 GO TO MENU NEXT PAGEPREVIOUS PAGE

Garry PairaudeauHead of Hit Discovery

AstraZeneca

Andy MerrittHead of Chemistry LifeArc Centre for

Therapeutics Discovery

Raghava Reddy Kethiri, PhD Chief Scientific Officer

LAXAI Life Science Pvt. Ltd.

Providing unique chemical tools to probe kinetoplastid biology and as hit-to-lead

candidates for drug discovery

Role of external drug discovery services in advancing the discovery pipeline

How will AI enhance Drug Design: Challenges and opportunities

Hit and Lead Generation: Selection of screening sets and strategies to maximise

success rates

• SP3 count and ‘3D-ness’ – does this impact on either fragment or hit like screening success?• ‘Protein target class’ focused sets – are they all just our imagination?• DNA encoded libraries – how big is too big?

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

• Provides an access to external drug discovery expertise• Meeting the quality and productivity expectation • Role of communication & documentation

SPEAKER TBC TBC TBC

TRACK 4 HIT TO LEAD IDENTIFICATION

PROVENTAI N T E R N A T I O N A L

9 GO TO MENU NEXT PAGEPREVIOUS PAGE

SPEAKER TBC TBC TBC

Guy LewyCSO

Sublime Therapeutics

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC

Connecting environmental exposure and neurodegeneration using cheminformatics:

potential and challenges

Software for Chemists: Desktop, Web and the Cloud

Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule

Collections and Libraries

Molecular adventures in 3D and 4D: What new ground is being opened up by

cloud computing?

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

TRACK 5 CHEMICAL BIOLOGY & CHEMINFORMATICS

PROVENTAI N T E R N A T I O N A L

10 GO TO MENU NEXT PAGEPREVIOUS PAGE

PJ MoloneyCEO P4ML

Jonathan HayPartner

Delin Ventures

Michael Bishop, Ph.D. Drug Discovery Specialist;

Ex-Director of Medicinal Chemistry of GSK Nanome

Targeting senescence cells

How Virtual Reality Can Positively Impact Global Drug Discovery Efforts

High-Throughput Screening Vs MultiOMICS

How to turn disruptive techonologies into sucessful businessess

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

• Why are drug discovery teams in pharma and biotechs adopting VR?• How has VR affected the global R&D around Covid-19?• What is the future of spatial computing for drug discovery?

SPEAKER TBC TBC TBC

TRACK 6 DISRUPTIVE TECHNOLOGIES

PROVENTAI N T E R N A T I O N A L

11 GO TO MENU NEXT PAGEPREVIOUS PAGE

Asif AhmedFounder

MirZyme Therapeutics

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC

How much influence do Investors play in making a decision on where to Outsource?

Cost vs Speed vs Quality?

TOPIC TBC

How a shared-risked partnership model can improve the success rates of getting

to IND

The Effect of Brexit on the Emerging Biopharm sector in the UK.

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

TRACK 7 OUTSOURCING FOR EMERGING BIOPHARMA

PROVENTAI N T E R N A T I O N A L

12 GO TO MENU NEXT PAGEPREVIOUS PAGE

Lassina BadoloDirector Discovery DMPK

Merck

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC

chosing the right technology at the right time to conduct ADME/Tox screening of a drug candidate, to save time and money

in the process of obtaining regulatory approval

TOPIC TBC

The use of AI for decision making in drug discovery: How applying AI in DMPK could

impact drug discovery

MetID and metabolite profiling

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

TRACK 8 DMPK & ADME

PROVENTAI N T E R N A T I O N A L

13 GO TO MENU NEXT PAGEPREVIOUS PAGE

Marcie Glicksman Head of Biology

EnClear Therapies

Mark Bittinger VP & Global Head of Biology

Sai Life Sciences

Isabel NajeraCSO

Virion Therapeutics

Optimizing Chemical Reactions with Deep Reinforcement Learning

Developing fit-for-purpose cell-based assaysfor mechanistic differentiation

Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug Discovery

What can we still learn from cell and animal models?

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

SPEAKER TBC TBC TBC

TRACK 9 IN VIVO & IN VITRO PHARMACOLOGY

PROVENTAI N T E R N A T I O N A L

14 GO TO MENU NEXT PAGEPREVIOUS PAGE

Matthew FyfeHead of Chemistry and

Intellectual Property Sitryx Therapeutics

David Cipolla VP of Research

Insmed Inc

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC

How to Complete a PoC without Depleting all Resources

TOPIC TBC

Bridging the gap between empirical drug discovery and rational drug development

How to get access to the secure enterprise ecosystem in order to launch your PoC.

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

TRACK 10 IND- PROOF OF CONCEPT

PROVENTAI N T E R N A T I O N A L

15 GO TO MENU NEXT PAGEPREVIOUS PAGE

Marc RamisCEO

Senolytic Therapeutics

Paul Peter Tak, MD PhDPresident & CEO

Kintai Therapeutics

SPEAKER TBC TBC TBC

Ignacio Quiles Vice President & Commercial

Director - Oncology Hematology GSK

How to improve current alliances and gain more effective collaborations

TOPIC TBC

Enabling business goals via collaborative or commercial alliances, both moderates risk

and garners reward

Implementing open innovation in the industry: Joining pharmaceuticals, biotechs and academica together to accelerate R&D

processes.

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

TRACK 11 STRATEGIC PARTNERSHIP & OUTSOURCING

PROVENTAI N T E R N A T I O N A L

16 GO TO MENU NEXT PAGEPREVIOUS PAGE

Rob HowesDirector Discovery Biology

AstraZeneca

Alun McCarthyVice President

C4X Discovery Ltd.

SPEAKER TBC TBC TBC

Joseph Mancini Head of Biology, Senior Director

adMare Bioinnovations

Validated Targets through Human Biology

TOPIC TBC

What is a validated target? Discussion on generating new targets

for drug discovery

Using Human Genetics to Identify Drug Targets

• Direct genetic support increases the probability of successful clinical development, addressing the critical issue of attrition• It is difficult to identify which genetic associations will lead to a big enough effect size in clinical studies• The challenge is to identify which associated genes - or near neighbours - warrant drug discovery investment

LEARN MORE ABOUT OUR SPEAKERS

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC

TRACK 12 TARGET VALIDATION

PROVENTAI N T E R N A T I O N A L

17

COMPANY

AB-ScienceABAC Therapeutics AbbvieAbbvieAbbvie AlmirallAmcureAnnexin PharmaceuticalAstraZenecaAstraZenecaAstrazenecaAstrazenecaAstrazenecaAstrazenecaAstrazenecaAstraZenecaAstrazenecaAstrazenecaBarts Clinical Trials Unit, Queen Mary University of Lon-donBayerBayerBergenbioBiogenBoehringer Ingelheim RCV GmbH & Co KGBridge BiotecBridge BiotechBrunel University LondonC4X Discovery Ltd.C4X Discovery Ltd.C4X Discovery Ltd.Centauri TherapeuticsDe Montfort UniversityE Therapeutics PlcE-TherapeuticsE-Therapeutics

JOB TITLE

Head of Computational chemistryChief Executive Officer & Founder Senior Director, Discovery Platform TechnologiesHead of Discovery Chemistry and Screening biologyVice President and Distinguished Research Fellow, Discovery Chemistry and TechnologySection Head Medicinal Chemistry IIChief Executive OfficerChief Scientific Officer and Chief Medical OfficerVice President, Global Head of Structure, Biophysics & Frag-ment-Based lead GenerationGlobal Head Oncology SafetyExecutive DirectorAssociate Principal ScientistAssociate DirectorLead ScientistSenior Scientist/Lead ScientistSenior Director, Medicinal Chemistry Director, Medicinal ChemistryHead of Hit DiscoveryDirectorVice President, Head Research PharmacokineticsDirector, Medicinal ChemistryCSOHead of Computational ChemistryScientific Director – Group LeaderDirector/CEOCEO/DirectorHead of Department of Life SciencesCSOVP Structural Design & Medicinal ChemistryVP Medicinal ChemistryHead of ChemistryProfessor of Biomedical Science, and Head of Biomedical and Environmental Health ResearchBusiness Development & Programme ManagerPrincipal Data ScientistHead of Discovery Informatics

ElasmogenEli LillyEli LillyForendo PharmaGeneuroGlaxoSmithKlineGSKGSkGSKGSKGSKGSkGSKGSKGSKGSK IdorsiaIdorsiaImperial College LondonInventivaIpsenIpsenJanssenJanssen PharmaceuticaJohnson Johnson KalVista PharmaceuticalsKarus Therapeutics Leo Pharma LifeArcLifeArcLundbeckMerckMerckMerck KGaAMerck SeronoMerck Sharp and Dohme Mirzyme TherapeuticsMirZyme TherapeuticsMirZyme Therapeutics

Chief Executive Officer and Chief Scientific OfficerDirector, Emerging Technologies and InnovationSenior Research ScientistHead of Drug DiscoverySenior Vice President, Head of Preclinical DevelopmentSenior MetaData ManagerResearch DirectorUK Director Structural Biology & BiophysicsVP, Mechanistic Safety Scientific Project LeadershipBig Data AnalystScientific LeaderResearch Director/ Sr. FellowResearch DirectorScientific LeaderDirector, Medicinal ChemistryComputational ChemistDiscovery Scientist & Head of LaboratoryProfessor of Cancer BiologyHead of ChemistryDirector – Toxins In VitroPrincipal ScientistHead, Computational ChemistryComputational ChemistSenior Director – New Ventures and TransactionsDirector of Medicinal ChemistryChief Operations Officer & Chief Scientific Officer Vice President of Research Head of ChemistryPrincipal ScientistDirector and Head of Medicinal ChemistryExecutive Director, Global Head Quantitative PharmacologyDirector, Global Head of Search & Evaluation Discovery TechnologiesAssociate DirectorDirector Discovery DMPK Executive DirectorECODirector for R&DSenior scientist/Research Fellow

COMPANY JOB TITLE

GO TO MENU NEXT PAGEPREVIOUS PAGE

2019 ATTENDEES p.1

PROVENTAI N T E R N A T I O N A L

18

COMPANY

NovartisNovartisNovartis Novo NordiskNovo NordiskOrion PharmaRedx PharmaRocheRocheRoche Innovation CenterSanofi

SanofiSanofiSanofiSanofiSentinel OncologySentinel Oncology LtdSilence TherapeuticsSosei HeptaresSummit TherapeuticsTopadur Pharma Topivert Pharma

JOB TITLE

Senior Investigator IInvestigator III / Lab Head Screening SciencesGlobal Head, External Science & Drug Discovery, Global Discovery ChemistryDirectorPrincipal Data ScientistDirector, Global Medicine DesignPrincipal ScientistGlobal Head Strategic Alliances, pRED InformaticsHead of Medicinal Chemistry Large Molecule Research Digital LeadVice President, Head of North America Diabetes and Cardiovascular Scientific Communications, North America Medical AffairsDirector Integrated Drug Discovery OutsourcingDirector, External Innovation in Drug DiscoverySection Head Small Molecular DesignHead External Innovation Drug DiscoveryDirector of ChemistryDirector of ChemistryVP, Head of Technology InnovationMedicinal Chemistry DirectorDirector, ChemistryChief Operating Officer Head of Biology

UCBUCBUCBUCLUniversity of BradfordUniversity of BristolUniversity of Central LancashireUniversity of GenevaUniversity of GlasgowUniversity of NottinghamUniversity of OxfordUniversity of SouthamptonUniversity of SurreyVernalisVertexVertexVifor PharmaVifor Pharma

Director, Structural Biology & BiophysicsDirector (Structural Biology and New Modalities)Principal Scientist CrystallographerSenior Research Associate/ Lead BiologistHead of Medicinal Chemistry Professor of Organic ChemistryChairman in BiosciencesProfessor and Director Professor of Chemical BiologyProfessor of Developmental PhysiologyMedicinal Chemistry AdvisorProfessor, Director of ResearchProfessor of RNA BiologyResearch DirectorPrincipal Research Fellow/ Head Biological SciencesHead of Chemistry, UKDirector and Head of ToxicologyHead of Chemical and Preclinical

COMPANY JOB TITLE

GO TO MENUPREVIOUS PAGE

2019 ATTENDEES p.2